EP3400214A4 - Dry powder inhaler compositions of 7-azoniabicyclo[2.2.1]heptane derivatives - Google Patents
Dry powder inhaler compositions of 7-azoniabicyclo[2.2.1]heptane derivatives Download PDFInfo
- Publication number
- EP3400214A4 EP3400214A4 EP17736492.4A EP17736492A EP3400214A4 EP 3400214 A4 EP3400214 A4 EP 3400214A4 EP 17736492 A EP17736492 A EP 17736492A EP 3400214 A4 EP3400214 A4 EP 3400214A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- azoniabicyclo
- dry powder
- powder inhaler
- heptane derivatives
- inhaler compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- SNZSSCZJMVIOCR-UHFFFAOYSA-N 7-azabicyclo[2.2.1]heptane Chemical group C1CC2CCC1N2 SNZSSCZJMVIOCR-UHFFFAOYSA-N 0.000 title 1
- 229940112141 dry powder inhaler Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662276778P | 2016-01-08 | 2016-01-08 | |
| PCT/US2017/012650 WO2017120559A1 (en) | 2016-01-08 | 2017-01-07 | Dry powder inhaler compositions of 7-azoniabicyclo[2.2.1]heptane derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| EP3400214A1 EP3400214A1 (en) | 2018-11-14 |
| EP3400214A4 true EP3400214A4 (en) | 2019-08-21 |
| EP3400214B1 EP3400214B1 (en) | 2024-03-13 |
Family
ID=59274459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP17736492.4A Active EP3400214B1 (en) | 2016-01-08 | 2017-01-07 | Dry powder inhaler compositions of 7-azoniabicyclo[2.2.1]heptane derivatives |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10835514B2 (en) |
| EP (1) | EP3400214B1 (en) |
| JP (1) | JP7015549B2 (en) |
| KR (1) | KR20180101438A (en) |
| CN (1) | CN108473437B (en) |
| CA (1) | CA3008292A1 (en) |
| MX (1) | MX2018008348A (en) |
| WO (1) | WO2017120559A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108473437B (en) | 2016-01-08 | 2022-03-25 | 西伦制药公司 | Dry powder inhaler compositions of 7-azabicyclo [2.2.1] heptane derivatives |
| WO2021070150A1 (en) * | 2019-10-11 | 2021-04-15 | Glenmark Specialty S.A. | An inhalable dry powder composition for pulmonary diseases |
| CN112679510A (en) * | 2020-12-23 | 2021-04-20 | 山东鲁抗医药股份有限公司 | 7-azabicyclo [2.2.1] heptane derivative bromide, preparation method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007022351A2 (en) * | 2005-08-18 | 2007-02-22 | Glaxo Group Limited | Muscarinic acetylcholine receptor antagonists |
| WO2011094434A2 (en) * | 2010-01-28 | 2011-08-04 | Theron Pharmaceuticals, Inc. | 7-azoniabicyclo [2.2.1] heptane derivatives, methods of production, and pharmaceutical uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0969816B1 (en) * | 1997-03-20 | 2004-12-15 | Schering Corporation | Preparation of powder agglomerates |
| US20070020299A1 (en) | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
| ES2257152B1 (en) | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | COMBINATIONS THAT INCLUDE ANTIMUSCARINIC AGENTS AND BETA-ADRENERGIC AGONISTS. |
| WO2014007771A2 (en) | 2012-07-05 | 2014-01-09 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Inhalation compositions comprising muscarinic receptor antagonist |
| CN108473437B (en) | 2016-01-08 | 2022-03-25 | 西伦制药公司 | Dry powder inhaler compositions of 7-azabicyclo [2.2.1] heptane derivatives |
-
2017
- 2017-01-07 CN CN201780006038.1A patent/CN108473437B/en active Active
- 2017-01-07 US US16/067,113 patent/US10835514B2/en active Active
- 2017-01-07 CA CA3008292A patent/CA3008292A1/en active Pending
- 2017-01-07 EP EP17736492.4A patent/EP3400214B1/en active Active
- 2017-01-07 WO PCT/US2017/012650 patent/WO2017120559A1/en active Application Filing
- 2017-01-07 MX MX2018008348A patent/MX2018008348A/en unknown
- 2017-01-07 JP JP2018536181A patent/JP7015549B2/en active Active
- 2017-01-07 KR KR1020187022176A patent/KR20180101438A/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007022351A2 (en) * | 2005-08-18 | 2007-02-22 | Glaxo Group Limited | Muscarinic acetylcholine receptor antagonists |
| WO2011094434A2 (en) * | 2010-01-28 | 2011-08-04 | Theron Pharmaceuticals, Inc. | 7-azoniabicyclo [2.2.1] heptane derivatives, methods of production, and pharmaceutical uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| US10835514B2 (en) | 2020-11-17 |
| US20190298690A1 (en) | 2019-10-03 |
| CN108473437B (en) | 2022-03-25 |
| CN108473437A (en) | 2018-08-31 |
| WO2017120559A1 (en) | 2017-07-13 |
| CA3008292A1 (en) | 2017-07-13 |
| KR20180101438A (en) | 2018-09-12 |
| JP2019506384A (en) | 2019-03-07 |
| EP3400214A1 (en) | 2018-11-14 |
| EP3400214B1 (en) | 2024-03-13 |
| JP7015549B2 (en) | 2022-02-03 |
| MX2018008348A (en) | 2018-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3407870A4 (en) | Dry powder inhaler | |
| EP3481402A4 (en) | Compounds, compositions, and methods for the treatment of disease | |
| EP3675859A4 (en) | Compounds, compositions, and methods for the treatment of disease | |
| EP3484504A4 (en) | Compounds, compositions, and methods for the treatment of disease | |
| EP3112364A4 (en) | 2,4-disubstituted phenylene-1,5-diamine derivatives and applications thereof, and pharmaceutical compositions and pharmaceutically acceptable compositions prepared therefrom | |
| EP3139920A4 (en) | Anti-viral compounds, pharmaceutical compositions, and methods of use thereof | |
| HK1231416A1 (en) | Complexes of sirolimus and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them | |
| EP3283151A4 (en) | Dry powder inhaler and method of use | |
| EP3107548B8 (en) | Dry powder formulations for inhalation | |
| EP3279207A4 (en) | Novel compound of 4'-thionucleoside, as well as preparation method therefor, pharmaceutical composition thereof and application thereof | |
| EP3452170A4 (en) | Dry powder treprostinil for the treatment of pulmonary hypertension | |
| EP3463277A4 (en) | Formulations for substituted 3-pyrrolidines, compositions containing, and uses of, same | |
| EP3487563A4 (en) | Dry powder inhaler | |
| EP3697791A4 (en) | Heterocyclic compounds, compositions comprising heterocyclic compound, and methods of use thereof | |
| EP3478284A4 (en) | Compounds and compositions for the treatment of cancer | |
| EP3647313A4 (en) | Substituted aryl ether compound, preparation method therefor, pharmaceutical composition and use thereof | |
| EP3793563A4 (en) | Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof | |
| EP3426671A4 (en) | Compounds and compositions for the treatment of infections | |
| EP3714928A4 (en) | Novel dry powder inhalation device | |
| EP3687551A4 (en) | Fluoro substituted porphyrin compounds, pharmaceutical compositions comprising the same, and methods of preparing and using the same | |
| EP3400214A4 (en) | Dry powder inhaler compositions of 7-azoniabicyclo[2.2.1]heptane derivatives | |
| EP3497077A4 (en) | Amide compounds, pharmaceutical compositions thereof, and methods of using the same | |
| EP3941438A4 (en) | Inhalable dry powders | |
| EP3463378A4 (en) | Dry powder formulations for inhalation | |
| EP3426238A4 (en) | Curcumin-based compositions&methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20180727 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20190723 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 9/00 20060101ALI20190717BHEP Ipc: A61K 31/40 20060101ALI20190717BHEP Ipc: A61K 47/26 20060101ALI20190717BHEP Ipc: C07D 487/08 20060101ALI20190717BHEP Ipc: C07D 221/22 20060101AFI20190717BHEP Ipc: A61P 11/06 20060101ALI20190717BHEP |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40000409 Country of ref document: HK |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20200610 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
| INTG | Intention to grant announced |
Effective date: 20230413 |
|
| GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| INTC | Intention to grant announced (deleted) | ||
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
| INTG | Intention to grant announced |
Effective date: 20231002 |
|
| GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602017079964 Country of ref document: DE |